Alireza Mohebbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alireza Mohebbi has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Fatemeh Sana Askari
Department of Microbiology, School of Medicine, Golestan Iran University of Medical Sciences, Gorgan, Iran
12 shared publicationsZahra Aliabadi
Golestan University of Medical Sciences
7 shared publicationsNaeme Javid
Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
6 shared publications- Alijan Tabarraei
Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
5 shared publications Azam Mirarab
Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
5 shared publicationsMohsen Ebrahimi
Children's Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
A descriptive framework for dose-resolved transcriptomic analysis reveals heterogeneous responses of Pseudomonas aeruginosa PAO1 to CuO nanoparticles
- 10 November 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Open AccessA descriptive framework for dose-resolved transcriptomic analysis reveals heterogeneous responses of Pseudomonas aeruginosa PAO1 to CuO nanoparticles
- Open Access
- 22 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0358847
All-atom molecular dynamics simulation of Cyclophilin A in complex with Sanglifehrin A
Cyclophilin A (CypA), a key peptidyl-prolyl cis/trans isomerase, plays a pivotal role in various biological processes and is a target for therapeutic intervention, particularly in viral and cancer-related diseases. This study explores the structural and dynamic effects of Sanglifehrin A (SangfA), a potent CypA inhibitor, using molecular dynamics (MD) simulation. All-atom MD simulations (100 ns) of apo CypA and its complex with SangfA were performed using GROMACS v2023. In addition to MD analyses, essential dynamics, clustering, secondary structure, and binding free energy were analyzed. SangfA binding induces a dual dynamic response: local rigidification of the active-site β2-β3 loop, residues 100–102 and 108–111 with a coil‑to‑β-strand transition (β-sheet content rises from 28.0% to 32.3%), alongside enhanced mobility in distal loops and a 1.1‑fold expansion of the conformational ensemble. Principal component analysis shows redistribution of motions from a single dominant mode (apo PC1 = 44.2%) to more diffuse fluctuations (holo PC1 = 30.4%), increasing configurational entropy. The ligand forms a dynamic hydrogen‑bond network (1–2 persistent bonds) anchored by Arg55 and hydrophobic contacts with Phe60 and Lys105, while Arg55 remains uninvolved. The computed binding free energy (ΔG = −20.45 ± 3.07 Kcal/mol) accords with picomolar potency. SangfA acts via conformational selection, stabilizing a pre‑existing CypA substate with augmented β-structure and broader dynamics. This entropically driven mechanism challenges static inhibition paradigms. Future efforts should validate the β2-β3 loop transition experimentally and exploit the Lys105 contact to design next‑generation cyclophilin inhibitors.
- 22 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0358847
Open AccessAll-atom molecular dynamics simulation of Cyclophilin A in complex with Sanglifehrin A
Cyclophilin A (CypA), a key peptidyl-prolyl cis/trans isomerase, plays a pivotal role in various biological processes and is a target for therapeutic intervention, particularly in viral and cancer-related diseases. This study explores the structural and dynamic effects of Sanglifehrin A (SangfA), a potent CypA inhibitor, using molecular dynamics (MD) simulation. All-atom MD simulations (100 ns) of apo CypA and its complex with SangfA were performed using GROMACS v2023. In addition to MD analyses, essential dynamics, clustering, secondary structure, and binding free energy were analyzed. SangfA binding induces a dual dynamic response: local rigidification of the active-site β2-β3 loop, residues 100–102 and 108–111 with a coil‑to‑β-strand transition (β-sheet content rises from 28.0% to 32.3%), alongside enhanced mobility in distal loops and a 1.1‑fold expansion of the conformational ensemble. Principal component analysis shows redistribution of motions from a single dominant mode (apo PC1 = 44.2%) to more diffuse fluctuations (holo PC1 = 30.4%), increasing configurational entropy. The ligand forms a dynamic hydrogen‑bond network (1–2 persistent bonds) anchored by Arg55 and hydrophobic contacts with Phe60 and Lys105, while Arg55 remains uninvolved. The computed binding free energy (ΔG = −20.45 ± 3.07 Kcal/mol) accords with picomolar potency. SangfA acts via conformational selection, stabilizing a pre‑existing CypA substate with augmented β-structure and broader dynamics. This entropically driven mechanism challenges static inhibition paradigms. Future efforts should validate the β2-β3 loop transition experimentally and exploit the Lys105 contact to design next‑generation cyclophilin inhibitors.
- Open Access
Cross-Kingdom Multi-Omics Harmonization Uncovers Coordinated Host Defense and Vector Small RNA Regulatory Networks in Begomovirus Transmission
Begomoviruses present severe threats to global crop production through complex vector-mediated transmission by the whitefly Bemisia tabaci to host plants such as tomato (Solanum lycopersicum). Unraveling the molecular dialogue between host immune activation and vector non-coding RNA networks is essential for identifying key drivers of virus persistence and transmission. Public host transcriptomic (GSE309527) and vector small RNA (sRNA) sequencing datasets (GSE111343) were processed through a multi-omics harmonization and signal calibration pipeline. Differential expression analysis was performed using empirical Bayes moderated linear models, followed by non-parametric Spearman rank correlation modeling ([[EQUATION]]) to infer cross-kingdom co-expression dynamics and pathway enrichment profiling across host and vector bio-systems. Harmonized principal component analysis showed clear separation by infection status across host plant and vector cohorts. Differential expression analysis identified 138 significantly altered host genes (69 upregulated, 69 downregulated) and 130 differentially expressed vector sRNAs (65 upregulated, 65 downregulated). Host responses were dominated by significant upregulation of gene-silencing machinery, including Suppressor of Gene Silencing 3 (SGS3; log2 FC = 3.67, q = 7.47 × 10-5), and pathway enrichment in Jasmonate defense (q = 0.0004) and RNA Interference & Silencing (q = 0.0001). Vector sRNAs exhibited targeted dynamic alterations, with pathway enrichment in Salivary Gland Secretion ($q = 0.0030) and Gut Endosymbiont Response (q = 0.0210). Cross-kingdom correlation modeling revealed two distinct, highly anticorrelated regulatory modules (mean [[EQUATION]] = 0.76). Host SGS3 expression strongly correlated with vector sRNA VEC_0080 ([[EQUATION]] = 0.9762) and virus-derived siRNA Bt-vsiRNA-01 ([[EQUATION]] = 0.7619). These findings demonstrate a tightly synchronized tripartite molecular crosstalk between host antiviral immunity, viral siRNA accumulation, and vector small RNA remodeling. These cross-kingdom regulatory modules highlight promising targets for dual-action RNA interference strategies aimed at controlling Begomovirus transmission.
Open AccessCross-Kingdom Multi-Omics Harmonization Uncovers Coordinated Host Defense and Vector Small RNA Regulatory Networks in Begomovirus Transmission
Begomoviruses present severe threats to global crop production through complex vector-mediated transmission by the whitefly Bemisia tabaci to host plants such as tomato (Solanum lycopersicum). Unraveling the molecular dialogue between host immune activation and vector non-coding RNA networks is essential for identifying key drivers of virus persistence and transmission. Public host transcriptomic (GSE309527) and vector small RNA (sRNA) sequencing datasets (GSE111343) were processed through a multi-omics harmonization and signal calibration pipeline. Differential expression analysis was performed using empirical Bayes moderated linear models, followed by non-parametric Spearman rank correlation modeling ([[EQUATION]]) to infer cross-kingdom co-expression dynamics and pathway enrichment profiling across host and vector bio-systems. Harmonized principal component analysis showed clear separation by infection status across host plant and vector cohorts. Differential expression analysis identified 138 significantly altered host genes (69 upregulated, 69 downregulated) and 130 differentially expressed vector sRNAs (65 upregulated, 65 downregulated). Host responses were dominated by significant upregulation of gene-silencing machinery, including Suppressor of Gene Silencing 3 (SGS3; log2 FC = 3.67, q = 7.47 × 10-5), and pathway enrichment in Jasmonate defense (q = 0.0004) and RNA Interference & Silencing (q = 0.0001). Vector sRNAs exhibited targeted dynamic alterations, with pathway enrichment in Salivary Gland Secretion ($q = 0.0030) and Gut Endosymbiont Response (q = 0.0210). Cross-kingdom correlation modeling revealed two distinct, highly anticorrelated regulatory modules (mean [[EQUATION]] = 0.76). Host SGS3 expression strongly correlated with vector sRNA VEC_0080 ([[EQUATION]] = 0.9762) and virus-derived siRNA Bt-vsiRNA-01 ([[EQUATION]] = 0.7619). These findings demonstrate a tightly synchronized tripartite molecular crosstalk between host antiviral immunity, viral siRNA accumulation, and vector small RNA remodeling. These cross-kingdom regulatory modules highlight promising targets for dual-action RNA interference strategies aimed at controlling Begomovirus transmission.
- Open Access
- 19 December 2025
- Published by MDPI AG in Preprints.org
Divergent Bacteriophages from Wastewater Reveal an Open Pan-Genome with No Shared Gene Families
Bacteriophages, the most abundant and genetically diverse biological entities, have much of their diversity unexplored. Wastewater systems with intact microbial com-munities serve as reservoirs for diverse phages. This study recovered complete phage genomes from rural wastewater metagenomes to assess their genetic diversity. Meta-genomic sequences from six wastewater samples were assembled, viral contigs identi-fied using PHASTEST, yielding 17 high-confidence phage genomes. These were anno-tated and compared via pangenome analysis, gene-sharing networks, phylogenetic re-construction, and average amino acid identity. Heaps’ law and UpSet plots quantified pangenome openness and gene family intersections. The 17 phage genomes encoded 30–172 proteins each, sharing no core genes. Of 1,031 gene families, 98.7% were “cloud” and 94% unique, with only 13 “shell” families in >2 phages. Most shared no genes (average Jaccard similarity < 1%), 15 appearing as isolated nodes in networks. Phylogenetic trees exhibited star-like topology, reflecting distinct paths. The pange-nome was open (Heaps’ law α ≈ 0.026), with minimal overlap confirmed by UpSet, and ancestral reconstruction indicated stable genomes with occasional gains. In conclusion, bacteriophages exhibit extreme genomic diversity even in one environment, each ge-nome largely unique, highlighting the immense uncharted phage diversity and sup-porting high diversity in varied habitats.
- 19 December 2025
- Published by MDPI AG in Preprints.org
Open AccessDivergent Bacteriophages from Wastewater Reveal an Open Pan-Genome with No Shared Gene Families
Bacteriophages, the most abundant and genetically diverse biological entities, have much of their diversity unexplored. Wastewater systems with intact microbial com-munities serve as reservoirs for diverse phages. This study recovered complete phage genomes from rural wastewater metagenomes to assess their genetic diversity. Meta-genomic sequences from six wastewater samples were assembled, viral contigs identi-fied using PHASTEST, yielding 17 high-confidence phage genomes. These were anno-tated and compared via pangenome analysis, gene-sharing networks, phylogenetic re-construction, and average amino acid identity. Heaps’ law and UpSet plots quantified pangenome openness and gene family intersections. The 17 phage genomes encoded 30–172 proteins each, sharing no core genes. Of 1,031 gene families, 98.7% were “cloud” and 94% unique, with only 13 “shell” families in >2 phages. Most shared no genes (average Jaccard similarity < 1%), 15 appearing as isolated nodes in networks. Phylogenetic trees exhibited star-like topology, reflecting distinct paths. The pange-nome was open (Heaps’ law α ≈ 0.026), with minimal overlap confirmed by UpSet, and ancestral reconstruction indicated stable genomes with occasional gains. In conclusion, bacteriophages exhibit extreme genomic diversity even in one environment, each ge-nome largely unique, highlighting the immense uncharted phage diversity and sup-porting high diversity in varied habitats.
- Open Access
- 15 October 2025
- Published by MDPI AG in Preprints.org
Profiling PIWI-Interacting RNAs in HBV-Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, with chronic hepatitis B virus (HBV) infection a major etiological factor. While microRNAs have been extensively studied in HCC, the role of PIWI-interacting RNAs (piRNAs) is at the beginning. Here, a comprehensive analysis was applied on small RNA sequencing data to compare piRNA expression in HBV-related HCC tumors, HBV-infected non-tumor liver, and normal liver tissue. RNA reads were aligned with Rsubread and quantified piRNAs using featureCounts, identifying differentially expressed piRNAs with DESeq2. In HBV-HCC versus normal liver 11 piRNAs found to be significantly dysregulated (5 up, 6 down), including a 9.9-fold upregulation of hsa-piR-32885 and 5.3-fold downregulation of hsa-piR-28734. Comparing HBV-HCC to HBV-infected liver revealed 17 differentially expressed piRNAs, with hsa-piR-432 most strongly upregulated. HBV-infected versus normal tissue showed 22 dysregulated piRNAs (21 down, 1 up), especially hsa-piR-432 was 21-fold down. These stage-specific changes suggest dynamic piRNA regulation during HBV-driven hepatocarcinogenesis. Many of the identified piRNAs are novel in the HCC context. Accordingly, hsa-piR-32885 has not been previously linked to liver cancer, though piR-Hep1 was found upregulated in ~47% of HCCs. The switch in hsa-piR-432 (down in HBV infection, up in HCC) highlights candidates for biomarkers or functional regulators. This study concludes that piRNA profiling in HBV-HCC uncovers novel markers and pathways. Future work will validate these piRNAs in larger cohorts and explore their regulatory targets. These findings support piRNAs as emerging players and biomarkers in HBV-associated HCC.
- 15 October 2025
- Published by MDPI AG in Preprints.org
Open AccessProfiling PIWI-Interacting RNAs in HBV-Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, with chronic hepatitis B virus (HBV) infection a major etiological factor. While microRNAs have been extensively studied in HCC, the role of PIWI-interacting RNAs (piRNAs) is at the beginning. Here, a comprehensive analysis was applied on small RNA sequencing data to compare piRNA expression in HBV-related HCC tumors, HBV-infected non-tumor liver, and normal liver tissue. RNA reads were aligned with Rsubread and quantified piRNAs using featureCounts, identifying differentially expressed piRNAs with DESeq2. In HBV-HCC versus normal liver 11 piRNAs found to be significantly dysregulated (5 up, 6 down), including a 9.9-fold upregulation of hsa-piR-32885 and 5.3-fold downregulation of hsa-piR-28734. Comparing HBV-HCC to HBV-infected liver revealed 17 differentially expressed piRNAs, with hsa-piR-432 most strongly upregulated. HBV-infected versus normal tissue showed 22 dysregulated piRNAs (21 down, 1 up), especially hsa-piR-432 was 21-fold down. These stage-specific changes suggest dynamic piRNA regulation during HBV-driven hepatocarcinogenesis. Many of the identified piRNAs are novel in the HCC context. Accordingly, hsa-piR-32885 has not been previously linked to liver cancer, though piR-Hep1 was found upregulated in ~47% of HCCs. The switch in hsa-piR-432 (down in HBV infection, up in HCC) highlights candidates for biomarkers or functional regulators. This study concludes that piRNA profiling in HBV-HCC uncovers novel markers and pathways. Future work will validate these piRNAs in larger cohorts and explore their regulatory targets. These findings support piRNAs as emerging players and biomarkers in HBV-associated HCC.
- Open Access
- 24 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators
Hepatitis B virus (HBV) remains a global health challenge. Capsid assembly modulators (CAMs) represent a promising class of antiviral agents that disrupt HBV core antigen (HBcAg) function. Understanding the structural and dynamic impact of CAMs on HBcAg is crucial for the development of next-generation antiviral therapies. This study employed molecular dynamics (MD) simulations to evaluate the conformational behavior of capsid monomers in unbound and ligand-bound states. Different classes of CAMs, Heteroaryldihydropyrimidine (HAP), Sulfamoylbenzamide (SBA), and Ciclopirox, were analyzed to assess their impact on HBcAg stability, flexibility, and interaction energy. RMSD analysis revealed that HAP binding stabilized HBcAg, reducing backbone fluctuations, whereas SBA and PPA increased HBcAg flexibility. RMSF calculations demonstrated that CAM interactions influenced loop and terminal region dynamics. PCA suggested ligand-specific alterations in HBcAg’s essential motions, with Sulfamoylbenzamide inducing the highest variance. Salt bridge analysis indicated that Ciclopirox formed the strongest electrostatic interactions, stabilizing its binding. DSSP secondary structure analysis showed that CAMs disrupted α-helical content, with Sulfamoylbenzamide and Ciclopirox exhibiting the most pronounced structural rearrangements. This study provides novel insights into CAM-induced conformational changes in HBcAg. While HAP stabilizes the core protein, SBA and Ciclopirox increase flexibility, potentially leading to misassembled or destabilized capsids. These findings contribute to the rational design of CAM-based antiviral therapies and highlight key structural determinants for future drug optimization.
- 24 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-21
Open AccessThe dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators
Hepatitis B virus (HBV) remains a global health challenge. Capsid assembly modulators (CAMs) represent a promising class of antiviral agents that disrupt HBV core antigen (HBcAg) function. Understanding the structural and dynamic impact of CAMs on HBcAg is crucial for the development of next-generation antiviral therapies. This study employed molecular dynamics (MD) simulations to evaluate the conformational behavior of capsid monomers in unbound and ligand-bound states. Different classes of CAMs, Heteroaryldihydropyrimidine (HAP), Sulfamoylbenzamide (SBA), and Ciclopirox, were analyzed to assess their impact on HBcAg stability, flexibility, and interaction energy. RMSD analysis revealed that HAP binding stabilized HBcAg, reducing backbone fluctuations, whereas SBA and PPA increased HBcAg flexibility. RMSF calculations demonstrated that CAM interactions influenced loop and terminal region dynamics. PCA suggested ligand-specific alterations in HBcAg’s essential motions, with Sulfamoylbenzamide inducing the highest variance. Salt bridge analysis indicated that Ciclopirox formed the strongest electrostatic interactions, stabilizing its binding. DSSP secondary structure analysis showed that CAMs disrupted α-helical content, with Sulfamoylbenzamide and Ciclopirox exhibiting the most pronounced structural rearrangements. This study provides novel insights into CAM-induced conformational changes in HBcAg. While HAP stabilizes the core protein, SBA and Ciclopirox increase flexibility, potentially leading to misassembled or destabilized capsids. These findings contribute to the rational design of CAM-based antiviral therapies and highlight key structural determinants for future drug optimization.
- 25 February 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (1) , 35
Computer-aided drug repurposing & discovery for Hepatitis B capsid protein
The primary objective of this study is to harness computer-aided drug repurposing (CADR) techniques to identify existing FDA-approved drugs that can potentially disrupt the assembly of the Hepatitis B Virus (HBV) core protein (HBcAg), an essential process in the virus’s life cycle. By targeting this critical step, our study aims to expand the repertoire of therapeutic options for managing chronic Hepatitis B infection, a major global health challenge. Utilizing a combination of computational methods, including the CavityPlus server for ability to analyze druggable protein cavities and extract pharmacophore features and LigandScout for pharmacophore-based virtual screening of a vast library of FDA-approved drugs was conducted. Molecular dynamic simulation (MDS) was employed to evaluate the stability of HBcAg, complexed with Heteroaryldihydropyrimidine (HAP) and statins exhibiting particularly strong binding energies and conformational compatibility. Our approach focused on identifying pharmacophore features that align with known HBcAg inhibitors. The study identified several promising candidates, including Ciclopirox olamine, Voriconazole, Enasidenib, and statins, demonstrating potential interactions with HBc protein residues. Molecular docking further validated these interactions. The significance of these findings lies in their potential to offer new, effective therapeutic strategies for HBV treatment, particularly as alternatives to current therapies that often suffer from issues of viral resistance and adverse side effects. MDS analysis verified the robustness of HAP and statins by showing a high level of binding energies and compatibility with HBcAg. Our results provide a foundation for further experimental validation and underscore the utility of computer-aided drug repurposing as a rapid, cost-effective approach to drug discovery in antiviral research. This study contributes to our understanding of HBV biology and opens avenues for developing novel anti-HBV therapies based on repurposed drugs. The highlighted compound may also enhance the challenges of drug resistance when used as a combination therapy.
- 25 February 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (1) , 35
Computer-aided drug repurposing & discovery for Hepatitis B capsid protein
The primary objective of this study is to harness computer-aided drug repurposing (CADR) techniques to identify existing FDA-approved drugs that can potentially disrupt the assembly of the Hepatitis B Virus (HBV) core protein (HBcAg), an essential process in the virus’s life cycle. By targeting this critical step, our study aims to expand the repertoire of therapeutic options for managing chronic Hepatitis B infection, a major global health challenge. Utilizing a combination of computational methods, including the CavityPlus server for ability to analyze druggable protein cavities and extract pharmacophore features and LigandScout for pharmacophore-based virtual screening of a vast library of FDA-approved drugs was conducted. Molecular dynamic simulation (MDS) was employed to evaluate the stability of HBcAg, complexed with Heteroaryldihydropyrimidine (HAP) and statins exhibiting particularly strong binding energies and conformational compatibility. Our approach focused on identifying pharmacophore features that align with known HBcAg inhibitors. The study identified several promising candidates, including Ciclopirox olamine, Voriconazole, Enasidenib, and statins, demonstrating potential interactions with HBc protein residues. Molecular docking further validated these interactions. The significance of these findings lies in their potential to offer new, effective therapeutic strategies for HBV treatment, particularly as alternatives to current therapies that often suffer from issues of viral resistance and adverse side effects. MDS analysis verified the robustness of HAP and statins by showing a high level of binding energies and compatibility with HBcAg. Our results provide a foundation for further experimental validation and underscore the utility of computer-aided drug repurposing as a rapid, cost-effective approach to drug discovery in antiviral research. This study contributes to our understanding of HBV biology and opens avenues for developing novel anti-HBV therapies based on repurposed drugs. The highlighted compound may also enhance the challenges of drug resistance when used as a combination therapy.
- Open Access
- 13 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0316765
Pharmacophore modeling and QSAR analysis of anti-HBV flavonols
Due to its global burden, Targeting Hepatitis B virus (HBV) infection in humans is crucial. Herbal medicine has long been significant, with flavonoids demonstrating promising results. Hence, the present study aimed to establish a way of identifying flavonoids with anti-HBV activities. Flavonoid structures with anti-HBV activities were retrieved. A flavonol-based pharmacophore model was established using LigandScout v4.4. Screening was performed using the PharmIt server. A QSAR equation was developed and validated with independent sets of compounds. The applicability domain (AD) was defined using Euclidean distance calculations for model validation. The best model, consisting of 57 features, was generated. High-throughput screening (HTS) using the flavonol-based model resulted in 509 unique hits. The model’s accuracy was further validated using a set of FDA-approved chemicals, demonstrating a sensitivity of 71% and a specificity of 100%. Additionally, the QSAR model with two predictors, x4a and qed, exhibited predictive solid performance with an adjusted-R2 value of 0.85 and 0.90 of Q2. PCA showed essential patterns and relationships within the dataset, with the first two components explaining nearly 98% of the total variance. Current HBV therapies tend to fail to provide a complete cure, emphasizing the need for new therapies. This study’s importance was to highlight flavonols as potential anti-HBV medicines, presenting a supplementary option for existing therapy. The QSAR model has been validated with two separate chemical sets, guaranteeing its reproducibility and usefulness for other flavonols by utilizing the predictive characteristics of X4A and qed. These results provide new possibilities for discovering future anti-HBV drugs by integrating modeling and experimental research.
- 13 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0316765
Open AccessPharmacophore modeling and QSAR analysis of anti-HBV flavonols
Due to its global burden, Targeting Hepatitis B virus (HBV) infection in humans is crucial. Herbal medicine has long been significant, with flavonoids demonstrating promising results. Hence, the present study aimed to establish a way of identifying flavonoids with anti-HBV activities. Flavonoid structures with anti-HBV activities were retrieved. A flavonol-based pharmacophore model was established using LigandScout v4.4. Screening was performed using the PharmIt server. A QSAR equation was developed and validated with independent sets of compounds. The applicability domain (AD) was defined using Euclidean distance calculations for model validation. The best model, consisting of 57 features, was generated. High-throughput screening (HTS) using the flavonol-based model resulted in 509 unique hits. The model’s accuracy was further validated using a set of FDA-approved chemicals, demonstrating a sensitivity of 71% and a specificity of 100%. Additionally, the QSAR model with two predictors, x4a and qed, exhibited predictive solid performance with an adjusted-R2 value of 0.85 and 0.90 of Q2. PCA showed essential patterns and relationships within the dataset, with the first two components explaining nearly 98% of the total variance. Current HBV therapies tend to fail to provide a complete cure, emphasizing the need for new therapies. This study’s importance was to highlight flavonols as potential anti-HBV medicines, presenting a supplementary option for existing therapy. The QSAR model has been validated with two separate chemical sets, guaranteeing its reproducibility and usefulness for other flavonols by utilizing the predictive characteristics of X4A and qed. These results provide new possibilities for discovering future anti-HBV drugs by integrating modeling and experimental research.
- Open Access
- 30 December 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (12) , 1855-1860
A cross-sectional study on the prevalence of multidrug-resistant clinical isolates of Proteus species in Northern Iran
Introduction: Multidrug-resistant (MDR) bacteria like Proteus species have led to more prolonged hospitalizations, fewer care choices, higher treatment costs, and even death. The present study aims to evaluate the prevalence of MDR Proteus species in clinical samples and to suggest the best therapeutic options for the MDR Proteus species. Methodology: Clinical samples were collected randomly from five hospitals in Golestan Province, Iran, from February 2017 to July 2019. Disk diffusion on Mueller–Hinton agar plates were used to perform antibiotic susceptibility testing (ASTs). By using a double-disc synergy test (DDST), isolates resistant to one of the third-generation cephalosporins were examined for phenotypic extended-spectrum β-lactamase (ESBL) development. A combined double disk synergy test (CDDST) was used to identify MBL-producing isolates. Results: 61 Proteus isolates, including P. Mirabilis 44/61 (77.04%), P. vulgaris 7/61 (11.47%), P. hauseri 5/61 (8.19%), and P. penneri 2/61 (3.27%) were collected. Most of the isolates were obtained from urine samples. P. hauseri isolates were more frequent in females. Resistance to tetracycline and nitrofurantoin antibiotics was observed in most Proteus isolates. P. penneri isolates were all resistant to antibiotics. ESBL production was observed in five ceftazidime-resistant isolates (p < 0.05). Conclusions: Cefepime and imipenem were found to have the lowest occurrence of antibiotic resistance among Proteus species, confirming that cefepime and imipenem can be used to treat Proteus infections.
- 30 December 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (12) , 1855-1860
Open AccessA cross-sectional study on the prevalence of multidrug-resistant clinical isolates of Proteus species in Northern Iran
Introduction: Multidrug-resistant (MDR) bacteria like Proteus species have led to more prolonged hospitalizations, fewer care choices, higher treatment costs, and even death. The present study aims to evaluate the prevalence of MDR Proteus species in clinical samples and to suggest the best therapeutic options for the MDR Proteus species. Methodology: Clinical samples were collected randomly from five hospitals in Golestan Province, Iran, from February 2017 to July 2019. Disk diffusion on Mueller–Hinton agar plates were used to perform antibiotic susceptibility testing (ASTs). By using a double-disc synergy test (DDST), isolates resistant to one of the third-generation cephalosporins were examined for phenotypic extended-spectrum β-lactamase (ESBL) development. A combined double disk synergy test (CDDST) was used to identify MBL-producing isolates. Results: 61 Proteus isolates, including P. Mirabilis 44/61 (77.04%), P. vulgaris 7/61 (11.47%), P. hauseri 5/61 (8.19%), and P. penneri 2/61 (3.27%) were collected. Most of the isolates were obtained from urine samples. P. hauseri isolates were more frequent in females. Resistance to tetracycline and nitrofurantoin antibiotics was observed in most Proteus isolates. P. penneri isolates were all resistant to antibiotics. ESBL production was observed in five ceftazidime-resistant isolates (p < 0.05). Conclusions: Cefepime and imipenem were found to have the lowest occurrence of antibiotic resistance among Proteus species, confirming that cefepime and imipenem can be used to treat Proteus infections.
- Open Access
- 1 October 2024
- Published by InkVista Publishing House in Journal of Clinical and Basic Research
- Vol. 8 (3) , 14-22
Metavirome survey of eight ray-finned fishes: Domination of giant viral members from pandoravirus and megaviricetes
Background: Fish are an essential source of food worldwide. Most microbial diversity in marine ecosystems remains uncharacterized, with viruses accounting for most of the remaining diversity. This poses a potential major threat to public health, making it critical to understand the variety of viruses in marine ecosystems. Our objective was to ...
- 1 October 2024
- Published by InkVista Publishing House in Journal of Clinical and Basic Research
- Vol. 8 (3) , 14-22
Open AccessMetavirome survey of eight ray-finned fishes: Domination of giant viral members from pandoravirus and megaviricetes
Background: Fish are an essential source of food worldwide. Most microbial diversity in marine ecosystems remains uncharacterized, with viruses accounting for most of the remaining diversity. This poses a potential major threat to public health, making it critical to understand the variety of viruses in marine ecosystems. Our objective was to ...